Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | MME | P08473 | 1/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9325914 | 0.81 | ALDH1A1 (0.49) | CA12CA1CA2CA9CYP1A2 | |
| SCHEMBL7309732 | 0.81 | ALDH1A1 (0.49) | CA12CA1CA2CA9CYP1A2 | |
| SCHEMBL7300596 | 0.81 | ALDH1A1 (0.49) | CA12CA1CA2CA9CYP1A2 | |
| SCHEMBL7332197 | 0.78 | KMT2A (0.50) | CA12CA1CA2CA9CYP1A2 | |
| SCHEMBL7368856 | 0.78 | NPC1 (0.54) | NPC1RAB9A | |
| SCHEMBL13386738 | 0.76 | NPC1 (0.59) | NPC1RAB9ACA12CA1CA2 | |
| SCHEMBL7141356 | 0.74 | EPHX2 (0.51) | NPC1CYP1A2MME | |
| SCHEMBL21122445 | 0.74 | ALPI (0.59) | NPC1RAB9A | |
| SCHEMBL1258101 | 0.74 | NPC1 (0.57) | NPC1RAB9ACYP1A2MMESLC1A3 | |
| SCHEMBL7155355 | 0.74 | CYP1A2 (0.68) | NPC1RAB9ACYP1A2MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030139419-A1 | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents | ASTRAZENECA AB (SE) | 2003-07-24 | — | — | US | disclosed |
| CN-1404474-A | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2003-03-19 | — | — | CN | disclosed |
| EP-1261595-A1 | ARYLPIPERAZINES AND ARYLPIPERIDINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS | AstraZeneca AB (SE) | 2002-12-04 | — | — | EP | disclosed |
| WO-2001062751-A1 | ARYLPIPERAZINES AND ARYLPIPERIDINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139419-A1 | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents | MMP13, MMP3, MMP2 | NPC1 1118/4885RAB9A 2998/4885CA12 1922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.